Medicare Compliance & Reimbursement - 2005 Issue 3
Chemotherapy: One Clinic Stands To Lose $150,000 On Drugs In 2005
Subscribe or sign in to view the full article.
Article Overview
This article examines the effect of 2005 Medicare drug reimbursement changes on oncology and infusion practices. It focuses on the financial strain caused by lower payments for commonly used cancer drugs and related medications, the response from CMS after provider feedback, and the broader operational concerns for clinics treating vulnerable patients. The piece is relevant to oncology billers, practice managers, compliance staff, and reimbursement professionals who monitor drug payment updates and practice revenue impact.
Why This Topic Matters
It highlights how reimbursement updates can quickly change drug profitability for oncology practices and why clinics need to monitor payment schedules, acquisition costs, and related service capture to assess financial exposure.
What You Will Learn
- How Medicare drug reimbursement changes can affect oncology practice finances
- Why acquisition cost and payment level mismatches matter for clinic operations
- How providers and CMS responded to reported payment shortfalls
- What operational issues arise when chemotherapy-related drug payments fall below costs
Who Should Read This
- Oncology billers
- Practice managers
- Compliance officers
- Infusion center staff
- Medical coders
- Reimbursement analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com